Premium Prucalopride Succinate API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Prucalopride Succinate (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Selective Serotonin 5-HT4 Receptor Agonist / Gastrointestinal Prokinetic

Indications: Chronic Idiopathic Constipation (CIC)

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Prucalopride Succinate distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Prucalopride Succinate is a highly potent, orally active small-molecule Active Pharmaceutical Ingredient (API). Within gastroenterological pharmacology, it is classified as a selective, high-affinity serotonin (5-HT4) receptor agonist. For pharmaceutical manufacturers expanding their gastrointestinal (GI) portfolios, this API represents a cornerstone for developing modern prokinetic therapeutics.

Unlike traditional laxatives that rely on osmotic or stimulant properties, Prucalopride Succinate targets the underlying neuromuscular dysfunction associated with severe motility disorders. At the physiological level, the API binds to 5-HT4 receptors located on the enteric neurons of the gastrointestinal tract.

By stimulating these specific receptors, the active ingredient facilitates the release of acetylcholine, the primary excitatory neurotransmitter in the enteric nervous system. This process triggers high-amplitude propagating contractions, effectively stimulating peristalsis and increasing the movement of waste through the bowel. It is highly selective for 5-HT4 receptors, demonstrating negligible affinity for 5-HT2A, 5-HT3, or hERG channels, which minimizes the cardiovascular side effects seen with older prokinetics.

For formulation scientists, integrating this API allows for the development of targeted, systemic treatments for patients suffering from chronic idiopathic constipation. In commercial manufacturing, this active ingredient is typically formulated into low-dose 1 mg and 2 mg film-coated oral solid tablets.

Sourcing Prucalopride Succinate in Pakistan: Morgan’s Supply Network

Developing and commercializing advanced gastrointestinal formulations requires a highly resilient and traceable raw material pipeline. Procuring specialty prokinetic APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and highly complex regulatory compliance. Sourcing PRUCALOPRIDE SUCCINATE Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether you are conducting pilot runs or require high-volume PRUCALOPRIDE SUCCINATE api Pakistan procurement, we help ensure that your commercial batch schedules and production timelines are met without costly line stoppages or raw material shortages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during blending, granulation, and tablet compression processes.

Technical Specifications for QA & R&D

The Prucalopride Succinate API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: 4-amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide butanedioate (succinate salt)
• CAS Number: 179474-85-2 (Succinate) / 179474-81-8 (Free Base)
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C18H26ClN3O3 · C4H6O4
• Molecular Weight: 485.96 g/mol (Succinate salt)
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Soluble in water and specific organic solvents. Detailed solubility parameters across standard solvents and aqueous buffers are documented in the technical data sheet to assist your analytical R&D teams with dissolution profiling and pre-formulation stability studies.

Manufacturing and Handling Guidelines for Formulators

Prucalopride Succinate is a pharmacologically active compound. Facilities processing this API must enforce standard occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature, strictly protected from excessive heat and ambient humidity) to prevent degradation and maintain the integrity of the succinate salt structure.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks or respirators, chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, milling, and blending stages must be executed within localized exhaust ventilation systems or dedicated weighing booths to prevent the inhalation of airborne particulates and facility cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.